DDW 2010/Guide/Abstracts/Coverage

[Guest guest]

DDW 2010/Guide/Abstracts/Coverage

DDW Index

..

Janis and Friends Will Keep You Updated With Two Different Sources

,

Blog :

Our Blog/ DDW Coverage : Study Result as they become available

****Link will be available on this blogs sidebar.

Website:

Our Website/ DDW Coverage: Videos, Audio, and Study Results updated as they become available

DDW is the largest educational forum for GI professionals from around the world. Join the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

From : J & F Blog.

Here are a few links and information to familiarize our readers with this years DDW ( Digestive Disease Week) ..

Each one of us will have an interest in the various topics , depending on what our own particular scenario is relating to HCV disease progression or treatment. .

We look forward to the outcome and will bring you updates as they become available. .

****As always we will keep an index of all the updates , the link will be available on this blogs sidebar..

Lectures .

The Treatment of Hepatitis C Virus Infection: Past, Present and Future .

• Identify host and viral factors associated with treatment response

• Incorporate response-guided therapy into treatment algorithms

• Evaluate the impact and management of anemia during interferon-based therapy

• Explore new treatment options with STAT-C agents and how they will impact patient responses

..Acute on Chronic Liver Failure.

• Identify patients with cirrhosis at risk of dying

• Define precipitating events

• Propose treatment options.

Minimal Encephalopathy: Why You Should Care About It.

• Understand the importance and prevalence of minimal hepatic encephalopathy

• Understand the methods for the diagnosis of minimal hepatic encephalopathy

• Understand the treatment strategies for minimal hepatic encephalopathyManagement

Strategies for Hepatocellular Cancer

• Understand treatment options for HCC

• Appreciate staging systems and algorithms for HCC

• Distinguish appropriate candidates for possibly curative therapy of HCC

Presenters

Onyx Pharmaceuticals/ Bayer Healthcare

http://www.onyx-pharm.com/

http://www.nexavar.com/

Company Overview:

Nexavar® (sorafenib) tablets is a novel, oral multi-kinase inhibitor targeting proteins involved in tumor cell proliferation and angiogenesis, developed by Bayer Healthcare and Onyx Pharmaceuticals. Nexavar is the first and only approved therapy for patients with unresectable HCC and is also approved for the treatment of patients with advanced RCC.This Exhibitor offers products & services in the following categories:• Pharmaceuticals» Prescription› Cancer

Merck

visit http://www.merck.com/

Company Overview:

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we would with customers and operate in more than 140 countries to deliver innovative health solution. Merck. Be Well. For more information,Brand Names: pegIntronThis Exhibitor offers products & services in the following categories:• Pharmaceuticals» Prescription› HCV

Vertex

http://www.vrtx.com/

Company Overview:

Vertex Pharmaceuticals is committed to the discovery & development of small molecule drugs for serious diseases. In collaboration with Tibotec, Vertex is developing telaprevir, an investigational HCV protease inhibitor in Phase 3 development. Vertex is also developing VX-222, an investigational HCV polymerase inhibitor in Phase 2 development.This Exhibitor offers products & services in the following categories:• Pharmaceuticals» Prescription› HCV

..

Some of the Abstracts that will be presented at the DDW.

Research Forum: HCV Therapy.

Abstract: High Dose Combination Therapy (Peginterferon Alfa-2a Plus Ribavirin) in Difficult-to-Cure Patients With Chronic Hepatitis C: Impact on Rvr, Cevr and SVR

Abstract: Anti-Viral Therapy and Risk Reduction in Liver Decompensation and Mortality in Hepatitis C Related Cirrhosis- a Systematic Review and Meta-Analysis

Abstract: the Hep573 Study - A Randomized Double Blind Placebo Controlled Trial of Silymarin Alone or Combined With Antioxidants in Chronic Hepatitis C

Abstract: Virologic and Metabolic Responses in Chronic Hepatitis C (CHC) Patients With Insulin Resistance (IR) Treated With Pioglitazone and Peginterferon Alfa-2a Plus Ribavirin

Abstract: Assessment of Paroxetine in the Prevention of Depression in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alpha Plus Ribavirin: A Multicentric, Double-Blinded, Randomized Study. Anrs Hc18 Paropeg

Poster Session: Clinical Hepatitis: Etiology, Diagnosis, Management and Natural History

Abstracts

..

Abstract: Fluvastatin May Enhance Early (EVR) and Sustained (SVR) Virological Response in Chronic Hepatitis C Treated With Peginterferon and Ribavirin. Is This a Consistent Effect or Pure Speculation?

Abstract: Influence of Il28b-Genotype on Response in Treatment-Naive Austrian Patients With Chronic Hepatitis Cl

Abstract: Up-Regulation of Matrix Metalloproteinase 9 (MMP-9) and Interleukin-8 (IL-8) in African-Americans Patients With Chronic Hepatitis C

Abstract: Predictive Factors for Silibinin Monotherapy in Patients With Chronic Hepatitis C and Nonresponse to PEG-IFN/RBV Therapy

Abstract: The Role of Liver Biopsy in the Diagnosis and Follow-up of Autoimmune Hepatitis

Abstract: Do Patients With Chronic Hepatitis C and Antibodies to Hepatitis B Core Antigen (anti-HBc) Have Increased Risk of Hepatocellular Carcinoma?

Abstract: Current Status of Alcoholic Liver Cirrhosis in Japan - Gender Difference and Factors Involved in the Progression

Abstract: Strong Predictors of Histologic Severity in Chronic Hepatitis B-Infected Patients Include Age, HBeAg Status and ALT Abnormality but Not the Viral Load

Abstract: Autoimmune Hepatitis in Elderly Is Usually an Advanced Disease at Presentation, Is Less Symptomatic and Relapse Is Infrequent.

Abstract: Predictors of Sustained Virological Response Among Patients With Hepatitis C Post OLT and the Impact of Sustained Virological Response on Mortality

Abstract: The Adequacy of Liver Biopsies Can Be Predicted From the Length of Fresh Tissue Obtained at the Time of Biopsy

Abstract: Role of 13C-Methacetin Breath Test for Noninvasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C Virus Infection

Abstract: Epidemiology and Management of Hepatitis B in Women of Childbearing Age at an Urban Medical Center

Abstract: Screening, Referral Practice and Management of Hepatitis B and C in Primary Care: A Survey of General Practitioners

Abstract: Suboptimal Treatment of Hyperlipidemia in Patients With Hepatitis C and Coronary Artery Disease,

Abstract: Impact of Ribavirin Priming on HCV Viral Clearance

Abstract: Effect of High-Dose Ribavirin (RBV), Alinia (Nitazoxanide) and Pegylated Interferon (Pegifn) Alfa-2a in Attaining Sustained Virologic Response (SVR) in Treatment of Chronic Hepatitis C (Erais-C Trial) in NaïVE Genotype 1 Patients

Abstract: The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection

Abstract: Decreased Sustained Virologic Response in Patients With Elevated Alanine Aminotransferase (ALT) During the Treatment of Chronic Hepatitis C

Abstract: The Effect of Type 2 Diabetes Mellitus on Sustained Virologic Response Rates for Hepatitis C Treatment Among Urban Patients at a Safety-Net Hospital

Abstract: Serum Immunoglobulins in Patients With Chronic Viral Hepatitis B and C Prior to Any Therapy

Poster Session: Liver Transplantation and Surgery

,

Abstract: Ductular Reaction in Hepatitis C Recurrence Post Liver Transplantation

Abstract: Relationship Between Treatment Related Anemia and SVR Rate in OLT Patients Treated With Peginterferon and Ribavirin

Abstract: The Impact of Combined Liver and Kidney Transplantation on Transplant Outcomes

Abstract: The Use of Beta-Blockers in Patients With Liver Cirrhosis Undergoing Liver Transplantation

Abstract: Prevalence, Determinants, and Prognostic Significance of Early Heart Failure in Patients With Liver Cirrhosis Undergoing Liver Transplantation

Abnormal Electrocardiographic Findings Are Common in Cirrhotic Patients Undergoing Liver Transplantation and Predict Post-Transplant Morbidity and Mortality

Abstract: Outcome of Liver Transplantation in Recipients Older Than 65 Years: A Single Center Experience

Abstract: Natural History of Cirrhosis After Orthotopic Liver Transplantation

Abstract: Predicting Survival Following Liver Transplant Using Artificial Neural Networks: Optimizing the Unos Database Using Machine Learning Techniques

Guide to Liver Sessions at DDW 2010

Additional Abstract Links

AASLD will provide exciting up-to-date educational research programs at Digestive Disease Week 2010 in New Orleans, Louisiana. This guide lists the liver-specific sessions offered by AASLD.

AASLD Research Highlights Advances in Hepatology: The Year in Review

Poster Session: Drug Toxicity and Metabolism

Poster Session: Clinical and Experimental Fibrosis

Poster Session: Complications of Liver Disease

Poster Session: Portal Hypertension and Other Complications of Cirrhosis

Browse Exhibitors by selecting from the categories below:Pharmaceuticals (33)Medical Equipment (62)Patient Care Supplies (13)

Professional Education (28)

Practice Management (20)

Other (87)

http://www.ddw.org/

http://Hepatitis Cnewdrugs.blogspot.com/2010/05/ddw-2010guideabstractscoverage.html